PeptideGrids

Semaglutide vs Tirzepatide vs Retatrutide

Comparing 3 compounds by evidence grade, FDA status, mechanism, and key safety considerations: Semaglutide, Tirzepatide, Retatrutide.

SemaglutideTirzepatideRetatrutide
Evidence gradeGrade A: Approved and provenGrade A: Approved and provenGrade B: Human evidence, not approved for this use
FDA statusFDA approved
Approved as Ozempic (subcutaneous injection, type 2 diabetes), Wegovy (subcutaneous injection 2.4 mg and oral 25 mg tablet, chronic weight management and cardiovascular risk reduction in obesity), and Rybelsus (oral tablet, type 2 diabetes).
FDA approved
Approved as Mounjaro (subcutaneous injection, type 2 diabetes) and Zepbound (subcutaneous injection, chronic weight management and, additionally, obstructive sleep apnea in adults with obesity).
Not FDA approved
Investigational; Phase 3 TRIUMPH trials ongoing as of June 2026, no NDA submitted.
MechanismSemaglutide is a GLP-1 receptor agonist that stimulates glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite via central and peripheral GLP-1 receptor activation.Tirzepatide is a dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptor agonist, which stimulates insulin secretion, suppresses glucagon, reduces appetite, and slows gastric emptying through activation of both receptor pathways.Simultaneously activates GLP-1, GIP, and glucagon receptors to suppress appetite, enhance insulin secretion in a glucose-dependent manner, and increase energy expenditure.
Key safetyBoxed warning: semaglutide causes thyroid C-cell tumors in rodents at clinically relevant exposures; human relevance is unknown but it is contraindicated in pat...Boxed warning: tirzepatide causes thyroid C-cell tumors in rats at clinically relevant exposures; human relevance is unknown and the drug is contraindicated in...As a GLP-1 receptor agonist, retatrutide carries the class risk of thyroid C-cell tumors observed in rodent studies; patients with personal or family history of...